|
Genzyme
Corporation Added to KLD's Domini 400 Social Index
BOSTON, MA - April 07, 2004 - KLD Research
& Analytics, Inc., an independent investment research
firm, announced today that Genzyme Corporation (GENZ)
has been added to KLD's Domini 400 SocialSM
Index (DS 400 Index). Genzyme Corporation is headquartered
in Cambridge, Massachusetts.
Genzyme
Corporation develops and manufactures drugs and
diagnostic and surgical products for chronic diseases
and serious medical conditions. The company's GelTex
subsidiary manufactures drugs to treat genetic diseases
and produces renal and diagnostic products. The
company's biosurgery unit develops and markets surgical
and biotherapeutic products for the orthopedic and
cardiothoracic markets. Its oncology unit focuses
on developing cancer vaccines and angiogenesis inhibitors.
Reasons
the company was added to KLD's DS 400 Index
- Genzyme
has demonstrated a strong commitment to supporting
public education in the life sciences. Genzyme
sponsors an annual Massachusetts Science Fair
award, grants for graduating high school seniors,
and provides funds the Boston Museum of Science
professional development program for science teachers.
-
Genzyme has made several notable commitments to
diversity in the Boston area. The company sponsors
The Partnership, Inc., an organization committed
to establishing a community of color that has
an influential presence in Boston. Genzyme provides
cash grants, mentors, and leadership from its
CEO, to the Biomedical Science Careers Program,
a New England regional program to encourage minority
participation in life sciences.
-
Through its employee option grant program, Genzyme
has made a significant commitment to employee
involvement. All U.S. employees are eligible for
the option grants.
-
The company has a policy against discrimination
based on sexual orientation and provides domestic
partner medical benefits to qualified partners.
About
the KLD Family of Indexes
KLD's Domini 400 Social Index (DS 400 Index) is
the established benchmark for measuring the impact
of social screening on financial performance. Launched
in May 1990, the DS 400 Index is the first benchmark
for equity portfolios subject to multiple social
screens. The index consists of 400 diversified equities
that pass a broad range of social screening criteria.
The KLD Broad Market SocialSM
Index (KLD BMS Index) is the screened subset of
the Russell 3000®
Index, and the KLD Large Cap SocialSM
Index (KLD LCS Index) is the screened subset of
the Russell 1000®
Index. The KLD BMS and LCS Indexes were launched
on January 1, 2001.
About KLD Research & Analytics, Inc.
KLD Research & Analytics, Inc. is an independent
investment research firm providing investment management
tools that are used by professionals to serve clients
requiring investment strategies based on social
and environmental responsibility. KLD products and
services, including Socrates (a web-based, company
research tool) are used for screening, compliance
and asset gathering.
For
more information about KLD or the KLD Domini 400
Social Index, please see our website (www.kld.com)
or contact Karen Agredo by phone (617.426.5270)
or via e-mail (kagredo@kld.com).
|
